文章摘要
包秋红,张 勇,贾海玉,曹中朝,孙 慧.芪参益气滴丸联合利拉鲁肽对老年2型糖尿病合并冠心病患者血糖、心功能及T细胞亚群的影响[J].,2020,(20):3897-3901
芪参益气滴丸联合利拉鲁肽对老年2型糖尿病合并冠心病患者血糖、心功能及T细胞亚群的影响
Effect of Qishenyiqi Pills Combined with Liraglutide on Blood Glucose, Cardiac Function and T Cell Subset of Elderly Patients with Type 2 Diabetes Combined with Coronary Heart Disease
投稿时间:2020-03-25  修订日期:2020-04-21
DOI:10.13241/j.cnki.pmb.2020.20.021
中文关键词: 2型糖尿病  冠心病  芪参益气滴丸  利拉鲁肽  血糖  心功能  T细胞亚群  疗效
英文关键词: Type 2 diabetes  Coronary heart disease  Qishenyiqi pills  Liraglutide  Blood glucose  Cardiac function  T cell subset  Efficacy
基金项目:内蒙古自治区卫生厅医疗卫生科研计划项目(2013264);内蒙古医科大学青年创新基金项目(YKD2016QNCX026)
作者单位E-mail
包秋红 内蒙古医科大学附属医院老年医学中心一病区 内蒙古 呼和浩特市 010059 nmgykd001@163.com 
张 勇 内蒙古医科大学附属医院老年医学中心一病区 内蒙古 呼和浩特市 010059  
贾海玉 内蒙古医科大学附属医院老年医学中心一病区 内蒙古 呼和浩特市 010059  
曹中朝 内蒙古医科大学附属医院老年医学中心一病区 内蒙古 呼和浩特市 010059  
孙 慧 内蒙古医科大学附属医院老年医学中心一病区 内蒙古 呼和浩特市 010059  
摘要点击次数: 608
全文下载次数: 377
中文摘要:
      摘要 目的:探讨芪参益气滴丸联合利拉鲁肽对老年2型糖尿病合并冠心病患者血糖、心功能及T细胞亚群的影响。方法:选择2017年1月到2019年6月我院收治的老年2型糖尿病合并冠心病患者105例,依照随机数字表法分为对照组(52例)和观察组(53例)。两组均给予常规治疗,对照组在常规治疗的基础上给予利拉鲁肽治疗,观察组在对照组基础上给予芪参益气滴丸治疗,两组均连续给予治疗8周。观察两组临床疗效,比较两组治疗前后血糖指标[空腹血糖(FPG)、餐后2 h血糖(2hPG)、糖化血红蛋白(HbAlc)],心功能[左室射血分数(LVEF)、左室舒张末期内径(LVEDD)、舒张早期最大峰值速度/舒张晚期最大峰值速度(E/A)]及外周血T细胞亚群CD4+、CD8+、CD4+/CD8+水平。记录两组治疗过程中的不良反应情况。结果:观察组的临床总有效率为96.23%(51/53),高于对照组的82.69%(43/52)(P<0.05)。治疗后,两组FPG、2hPG及HbAlc水平均较治疗前降低(P<0.05),且观察组低于对照组(均P<0.05);LVEF、E/A均升高,LVEDD降低(均P<0.05),观察组LVEF、E/A、LVEDD的改善情况均优于对照组(P<0.05);CD4+、CD4+/ CD8+水平均高于治疗前(P<0.05),同时观察组CD4+、CD4+/CD8+水平均高于对照组(P<0.05),两组治疗前后CD8+均无明显变化(P>0.05)。治疗期间,观察组的不良反应发生率为9.43%(5/53),对照组为9.62%(5/52),两组比较差异无统计学意义(x2=0.001,P=0.975)。结论:芪参益气滴丸联合利拉鲁肽治疗老年2型糖尿病合并冠心病的临床疗效较好,有助于改善患者血糖水平和心功能,提高机体免疫功能,且安全性较好。
英文摘要:
      ABSTRACT Objective: To explore the effect of qishenyiqi pills combined with liraglutide on blood glucos, cardiac function and T cell subset of elderly patients with type 2 diabetes combined with coronary heart disease. Methods: 105 cases of elderly patients with type 2 diabetes combined with coronary heart disease in our hospital from 2017 January to July 2019 were selected. According to the random indicator method, they were divided into the control group (n=52 cases) and the observation group (n=53 cases). Both groups were given routine treatment, patients of the control group were treated with liraglutide on the basis of the conventional treatment, while the observation group were treated with qishenyiqi pills combined with liraglutide on the basis of the control group. The two groups were treated for 8 weeks. Clinical curative effect of the two groups was observed. The blood sugar index [fasting plasma glucose (FPG), 2 h postprandial blood glucose (2hPG), glycosylated hemoglobin (HbAlc)], cardiac function [left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), the maximum peak early diastolic velocity/late diastolic peak velocity (E/A) largest] and peripheral blood T cell subsets CD4+, CD8+ and CD4+/CD8+ levels of the two groups before and after treatment were compared. The adverse reactions of the two groups during treatment were recorded. Results: Total effective rate of observation group was 96.23%(51/53), which was higher than 82.69%(43/52)of the control group (P<0.05). After treatment, the FPG, 2hPG, HbAlc of the two groups were lower than those before treatment (P<0.05). And those of the observation group were lower than those of the control group (all P<0.05). LVEF and E/A were increased, while LVEDD was decreased (all P<0.05). The improvement of LVEF, E/A and LVEDD of the observation group were better than those of the control group (P<0.05). CD4+ and CD4+/CD8+ levels were higher than those before treatment (P<0.05). Meanwhile, CD4+ and CD4+/CD8+ levels of the observation group were higher than those of the control group (P<0.05). There was no significantly difference of the CD8+ of the two groups before and after treatment (P>0.05). During treatment, the adverse reaction rate of the observation group was 9.43%(5/53), that of the control group was 9.62%(5/52), and there was no significantly difference of the two groups(x2=0.001,P=0.975). Conclusion: Qishenyiqi pills combined with lilalutide has a good clinical effect in the treatment of elderly type 2 diabetes with coronary heart disease, which is helpful to improve the blood glucose level and heart function, improve the immune function of the body, and which has a good safety.
查看全文   查看/发表评论  下载PDF阅读器
关闭